PATENT CLAIM ANALYSIS

Application Number: 16241596
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["544", "238000"]

Abstract:
Disclosed herein is the compound (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido)pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide, and salt forms and polymorphs thereof demonstrating improved exposure after oral dosing. Methods of inhibition GLS1 activity in a human or animal subject are also provided.

Claim (Index 1):
A method of inhibiting GLS1 activity in a biological sample comprising contacting the biological sample with the compound or a salt, solvate, or polymorph thereof.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 99.0
- Lexical Diversity: 1.28889
- Patent Class: 544.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15387560', '14272689', '14791186', '09961969', '15672627']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.731657471721382
- 35 USC 102 Novelty (BERT): 0.5154712994874705
- Combined Prediction Score: 0.7100388544979908
- Mean Citation Score: 298.5052980000001
- Max Citation Score: 313.40826
- Similarity Product: 260.09993301920053

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test